“…It has been shown that the presence of one protomer can alter membrane localization (Ellis et al, 2006;Rozenfeld et al, 2012), the affinity and/or efficacy of agonists (Martin and Prather, 2001;Rozenfeld et al, 2012;Wang et al, 2005), and signaling specificity (Charles et al, 2003;Rozenfeld et al, 2012) for the other promoter. Moreover, ligand binding to the orthosteric site of one promoter can change the pharmacological properties of orthosteric ligands for the other protomer (Ferre et al, 2016;Shivnaraine et al, 2016;Vischer et al, 2011). For example, apelin binding to its receptor reduces the binding and efficacy of angiotensin II acting at the angiotensin II Type 1 receptor via negative cooperativity between the protomers of the heteromer (Siddiquee et al, 2013).…”